ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TERT/Anti-CD3 T-cell Engager CBX-663

Its studies are led by Crossbow Therapeutics.

Furthest: phase 1, since Aug 7, 20261 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Crossbow Therapeutics11 open or runningphase 1since Aug 7, 2026Aug 7, 2026Jan 2028phase 1 · NCT07779798

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2026First study: phase 1 study in RecurrenceFirst studyNCT07779798 · 120 planned · United States

Ahead

  1. Jan 2028Primary completion: phase 1 study in RecurrenceNCT07779798

TargetBeta

CD3E →TERT →read by rule
“A T-cell receptor-mimetic (TCRm)-based bispecific T-cell engager (TCE) antibody that bivalently targets the human telomere reverse transcriptase (TERT) 540-548 (TERT540) peptide/human leukocyte antigen (HLA)-A*02:01 complex, and simultaneously targets the T-cell surface antigen CD3, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07779798Recurrence · United States1RecruitingJan 2028120

How it is read

Names in the registry

  • “CBX-663”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.